Kalaris Therapeutics, Inc.

NASDAQ:KLRS USA Biotechnology

Market Cap

$159.34 Million

Market Cap Rank

#26612 Global

#8985 in USA

Share Price

$8.52

Change (1 day)

-3.29%

52-Week Range

$2.27 - $11.40

All Time High

$11.40

Kalaris Therapeutics, Inc. - Asset Resilience Ratio

Latest as of September 2025: 42.64%

Kalaris Therapeutics, Inc. (KLRS) has an Asset Resilience Ratio of 42.64% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$34.61 Million

Cash + Short-term Investments

Total Assets

$81.17 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2021)

This chart shows how Kalaris Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Kalaris Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$34.61 Million	42.64%
Total Liquid Assets	$34.61 Million	42.64%

Asset Resilience Insights

Very High Liquidity: Kalaris Therapeutics, Inc. maintains exceptional liquid asset reserves at 42.64% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.